Crohn's Disease Treatment Study
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
- Sex: Any
- Age: Adult (18 - 64)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Colon, Small Intestine, Crohns Disease
Study Purpose
This is a follow up study for those that participated in an originator adult mirikizumab CD study. The purpose of this study is to determine whether mirikizumab (LY3074828) can help patients with Crohn’s disease when taken for a longer time and how safe mirikizumab is and whether you might have any side effects when you take it for a long time.
Who Can Participate
Must have participated in AMAG or AMAM studies
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
UH Ahuja Medical Center
3999 Richmond Rd
Beachwood OH, 44122
UH Minoff Health Center at Chagrin Highlands
3909 Orange Pl
Orange Village OH, 44122
- UH IRB: SITE00001181
- StudyID: 2020-0142
- ClinicalTrials.gov: NCT02105849
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422